Welcome to our dedicated page for Outlook Therapeutics news (Ticker: OTLKW), a resource for investors and traders seeking the latest updates and insights on Outlook Therapeutics stock.
News for OTLKW reflects developments at Outlook Therapeutics, Inc., a biopharmaceutical company concentrated on ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma), an ophthalmic formulation of bevacizumab for retinal diseases such as wet age-related macular degeneration (wet AMD). Company news frequently reiterates this focus on enhancing or optimizing the standard of care for bevacizumab in retina indications.
Readers can expect coverage of regulatory milestones, including interactions with the U.S. Food and Drug Administration (FDA) around the Biologics License Application (BLA) for ONS-5010. Recent announcements have described complete response letters, Type A meetings, BLA resubmissions, and FDA acknowledgments of resubmissions as complete, along with associated Prescription Drug User Fee Act (PDUFA) goal dates. These updates provide context on the regulatory pathway for the investigational product in the United States.
The OTLKW news feed also includes information on European commercialization of LYTENAVA™ (bevacizumab gamma), where Outlook Therapeutics reports that the product has received Marketing Authorization from the European Commission and the UK MHRA for the treatment of wet AMD and has been launched commercially in Germany and the UK. News items describe initial sales into distribution channels, early prescribing trends, and efforts to expand into additional European markets, subject to pricing and reimbursement approvals in certain Member States.
Additional news topics include corporate and investor events, such as participation in healthcare conferences, presentations at ophthalmology-focused meetings, and the appointment of senior executives in corporate strategy and business development. Disclosures on stock option grants to new employees as employment inducement awards may also appear. For investors and observers following OTLKW, this news page offers a centralized view of Outlook Therapeutics’ reported clinical, regulatory, commercial, and corporate developments related to its ophthalmic bevacizumab program.
Outlook Therapeutics announced the closing of an underwritten public offering of 46 million shares at $1.25 each, generating gross proceeds of $57.5 million. These funds will support the development of ONS-5010, an ophthalmic formulation of bevacizumab, with an expected biologics license application submission to the FDA in early 2023. The offering was managed by H.C. Wainwright & Co. The shares were offered under a shelf registration statement originally filed in March 2021. This move positions the company to advance its lead product for treating retinal diseases.
Outlook Therapeutics announced a public offering of 40 million shares of common stock at $1.25 per share, totaling expected gross proceeds of $50 million. The offering was increased due to demand, with H.C. Wainwright & Co. as the sole book-running manager. A 30-day option for an additional 6 million shares is also available. GMS Ventures, linked to a major stockholder, indicated interest in purchasing up to $20 million of the offering. Proceeds will support the development of ONS-5010, a potential FDA-approved ophthalmic treatment.
Outlook Therapeutics announced an underwriting agreement with H.C. Wainwright & Co. for 8,000,000 shares of common stock at $1.25 per share, projected to raise approximately $10 million. The offering closes on November 29, 2021, pending customary conditions. An additional 1,200,000 shares may be purchased by the underwriter. The funds will be utilized for working capital and corporate purposes, supporting the ONS-5010 development program. The shares are offered under an effective SEC registration statement.
Outlook Therapeutics has announced highly significant results from the Phase 3 NORSE TWO trial of ONS-5010, an ophthalmic formulation of bevacizumab, designed for wet age-related macular degeneration (wet AMD). The trial demonstrated that 41.7% of patients gained at least 15 letters in vision and met both primary and secondary endpoints. The company plans to submit a BLA to the U.S. FDA in Q1 2022, aiming for ONS-5010 to be the first FDA-approved ophthalmic bevacizumab, which could provide significant benefits for AMD patients.
Outlook Therapeutics (Nasdaq: OTLK) will host a Virtual Investor Roundtable Event on November 16, 2021, at 9:00 AM ET. Management, including President C. Russell Trenary and COO Terry Dagnon, will discuss the development of ONS-5010 (LYTENAVA™), the first FDA-approved ophthalmic formulation of bevacizumab for retinal diseases. Key thought leaders, Firas M. Rahhal, MD, and Robert L. Avery, MD, will join the discussion. A live video webcast will be accessible on their website and a replay will be available for one year.
Outlook Therapeutics, Inc. (Nasdaq: OTLK) announced that Dr. Firas M. Rahhal will present pivotal Phase 3 data from the NORSE TWO trial on November 13, 2021. This presentation will cover the safety and efficacy of ONS-5010 / LYTENAVA™, an investigational ophthalmic formulation of bevacizumab for retinal conditions. The event takes place during the Retina Subspecialty Day at the American Academy of Ophthalmology (AAO) 2021 Annual Conference in New Orleans. If approved, ONS-5010 is expected to be the first FDA-approved ophthalmic formulation of bevacizumab, targeting wet AMD and other retinal diseases.
Outlook Therapeutics presents at Eyecelerator@AAO 2021 Conference
ISELIN, N.J., Nov. 3, 2021 - Outlook Therapeutics (Nasdaq: OTLK) announced that CEO C. Russell Trenary will present at the Eyecelerator@AAO 2021 Retina Showcases in New Orleans on November 11, 2021, from 1:10 PM to 1:15 PM EST. The company focuses on developing ONS-5010/LYTENAVA™, the first FDA-approved ophthalmic formulation of bevacizumab for retinal diseases such as wet AMD and DME. If approved, it could be the only FDA-approved ophthalmic formulation of this drug in various global markets.
Outlook Therapeutics presented strong safety data from the NORSE THREE study of ONS-5010 at the 39th Annual Meeting of the American Society of Retina Specialists. The trial demonstrated no unexpected safety trends, with adverse events primarily related to injection procedures. ONS-5010 is being developed as the first FDA-approved ophthalmic formulation of bevacizumab for retinal diseases. The company plans to submit a BLA in early 2022, which, if approved, could lead to 12 years of marketing exclusivity for ONS-5010. This formulation aims to replace off-label alternatives currently in use.
Suber Huang, MD, MBA, FASRS will present safety data from Outlook Therapeutics’ NORSE THREE registration trial on October 12, 2021. The study focuses on ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational formulation for retinal indications. The presentation will occur at the 2021 Annual Meeting of the American Society of Retina Specialists in San Antonio, Texas, highlighting safety results in patients with wet AMD, DME, and BRVO. If approved, ONS-5010 is expected to be the first FDA-approved ophthalmic formulation of bevacizumab.
Outlook Therapeutics will showcase its innovations at the OIS Retina Innovation Showcase on October 7, 2021. C. Russell Trenary, President and CEO, will present the company's mission to introduce the first FDA-approved ophthalmic formulation of bevacizumab for retinal conditions. The presentation is set for 8:55 AM CT, followed by a panel with Jeff Evanson, Chief Commercial Officer, at 4:35 PM CT. Their product, ONS-5010/LYTENAVA™, aims to treat wet AMD, DME, and BRVO, targeting U.S. and international markets.